首页> 外文会议>Western Pharmacology Society >Treatment with LA-419 Prevents Monocrotaline-Induced Pulmonary Hypertension and Lung Injury in the Rat
【24h】

Treatment with LA-419 Prevents Monocrotaline-Induced Pulmonary Hypertension and Lung Injury in the Rat

机译:用LA-419治疗可防止大鼠肺动脉高压和大鼠肺损伤

获取原文

摘要

We evaluated the therapeutic potential of LA-419, a hybrid organic nitrate that donates nitric oxide and thiol groups, to improve pulmonary arterial hypertension in an experimental model induced by monocrotaline in the rat. Treatment with LA-419 from the first day after monocrotaline administration prevented the increase in pulmonary pressure as well as the increases in ventricle/body weight and pulmonary artery wall thickness. Administration of LA-419 after establishment of hypertensive status also resulted in an improvement of these parameters. Both preventive and therapeutic treatments reduced mortality. The antioxidant effect of LA-419 was comparable to that achieved with alpha-tocopherol. Pulmonary remodeling accomplished by LA-419 could be attributed to a balanced antioxidant effect associated with its nitric oxide/SH donor capability. Thus, LA-419 might represent a new therapeutic approach in severe pulmonary hypertension in humans.
机译:我们评估了La-419的治疗潜力,一种含有一氧化氮和硫醇基团的杂交有机硝酸盐,以改善大鼠偏霉素诱导的实验模型中的肺动脉高血压。 Monocrotaline给药后第一天治疗La-419,防止了肺压力的增加以及心室/体重和肺动脉厚度的增加。在建立高血压状态后,LA-419也导致了这些参数的改善。既有预防和治疗治疗也降低了死亡率。 La-419的抗氧化效果与α-生育酚达到的抗氧化效果相当。由LA-419实现的肺重塑可归因于与其一氧化氮/ SH体供体相关的平衡抗氧化效果。因此,LA-419可能代表人类严重肺动脉高压的新治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号